{"id":56201,"date":"2013-06-11T23:52:16","date_gmt":"2013-06-11T22:52:16","guid":{"rendered":"http:\/\/www.pressenza.com\/?p=56201"},"modified":"2013-06-11T23:54:07","modified_gmt":"2013-06-11T22:54:07","slug":"la-sage-decision-de-linde-2","status":"publish","type":"post","link":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/","title":{"rendered":"La sage d\u00e9cision de l\u2019Inde"},"content":{"rendered":"<p data-line-id=\"d2ec09039b58c2fc11912b43\"><strong>Par\u00a0<a itemprop=\"name\" href=\"http:\/\/www.project-syndicate.org\/contributor\/joseph-e--stiglitz\" rel=\"author\">Joseph E. Stiglitz<\/a>\u00a0et\u00a0<a itemprop=\"name\" href=\"http:\/\/www.project-syndicate.org\/contributor\/arjun-jayadev\" rel=\"author\">Arjun Jayadev<\/a><br \/>\n<\/strong><\/p>\n<p data-line-id=\"d2ec09039b58c2fc11912b43\">Le rejet par la Cour Supr\u00eame de New Delhi de la demande de brevet d\u00e9pos\u00e9e par le g\u00e9ant pharmaceutique suisse Novartis sur le Glivec, un m\u00e9dicament vedette contre le cancer, est une bonne nouvelle pour les malades indiens atteints d\u2019un cancer. Si d\u2019autres pays en d\u00e9veloppement suivent l\u2019exemple de l\u2019Inde, ce sera \u00e9galement une bonne nouvelle dans d\u2019autres domaines\u00a0: plus d\u2019argent pourra \u00eatre consacr\u00e9 \u00e0 d\u2019autres besoins, que ce soit la lutte contre le sida, l\u2019\u00e9ducation ou les investissements destin\u00e9s \u00e0 r\u00e9duire la pauvret\u00e9 et encourager la croissance.<\/p>\n<p data-line-id=\"d2ec09039b58c2fc11922b43\">Mais la d\u00e9cision de la Cour Supr\u00eame indienne signifie aussi moins d\u2019argent pour les laboratoires pharmaceutiques multinationaux, qui ont sans surprise r\u00e9agi de mani\u00e8re exc\u00e9d\u00e9e en all\u00e9guant que ce jugement \u00ab\u00a0allait d\u00e9courager l&rsquo;innovation future en Inde\u00a0\u00bb, et qu\u2019il constituait un s\u00e9rieux revers pour la sant\u00e9 publique dans le monde.<\/p>\n<p data-line-id=\"d2ec09039b58c2fc11932b43\">Ces affirmations sont largement exag\u00e9r\u00e9es. Le jugement de la Cour Supr\u00eame indienne fait sens, tant du point de vue \u00e9conomique qu\u2019en termes de politique sociale. Il n\u2019est de plus qu\u2019une tentative locale de r\u00e9\u00e9quilibrer un r\u00e9gime de propri\u00e9t\u00e9 intellectuelle (PI) qui penche trop en faveur des int\u00e9r\u00eats pharmaceutiques, au d\u00e9triment du bien-\u00eatre social. Il existe en fait un consensus croissant parmi les \u00e9conomistes sur le fait que le r\u00e9gime actuel de PI \u00e9touffe en r\u00e9alit\u00e9 l\u2019innovation.<\/p>\n<p>L&rsquo;article complet se trouve ici: <a href=\"http:\/\/www.project-syndicate.org\/commentary\/the-impact-of-the-indian-supreme-court-s-patent-decision-by-joseph-e--stiglitz-and-arjun-jayadev\/french#Jf3jSDzisBoBxRF7.99\">http:\/\/www.project-syndicate.org\/commentary\/the-impact-of-the-indian-supreme-court-s-patent-decision-by-joseph-e&#8211;stiglitz-and-arjun-jayadev\/french#Jf3jSDzisBoBxRF7.99<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Par\u00a0Joseph E. Stiglitz\u00a0et\u00a0Arjun Jayadev Le rejet par la Cour Supr\u00eame de New Delhi de la demande de brevet d\u00e9pos\u00e9e par le g\u00e9ant pharmaceutique suisse Novartis sur le Glivec, un m\u00e9dicament vedette contre le cancer, est une bonne nouvelle pour les&hellip;<\/p>\n","protected":false},"author":19,"featured_media":56205,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[84,98,100,40],"tags":[5394,5398,5396,813,5397,5395],"class_list":["post-56201","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-asia-fr","category-droits-de-lhomme","category-economie","category-international-fr","tag-brevet","tag-cancer-fr","tag-glivec","tag-inde","tag-medicament","tag-novartis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La sage d\u00e9cision de l\u2019Inde<\/title>\n<meta name=\"description\" content=\"Par\u00a0Joseph E. Stiglitz\u00a0et\u00a0Arjun Jayadev Le rejet par la Cour Supr\u00eame de New Delhi de la demande de brevet d\u00e9pos\u00e9e par le g\u00e9ant pharmaceutique suisse\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La sage d\u00e9cision de l\u2019Inde\" \/>\n<meta property=\"og:description\" content=\"Par\u00a0Joseph E. Stiglitz\u00a0et\u00a0Arjun Jayadev Le rejet par la Cour Supr\u00eame de New Delhi de la demande de brevet d\u00e9pos\u00e9e par le g\u00e9ant pharmaceutique suisse\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Pressenza\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/PressenzaItalia\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/pressenza\" \/>\n<meta property=\"article:published_time\" content=\"2013-06-11T22:52:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2013-06-11T22:54:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pressenza.com\/wp-content\/uploads\/2013\/06\/Medicament.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"532\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pressenza IPA\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@PressenzaIPA\" \/>\n<meta name=\"twitter:site\" content=\"@PressenzaIPA\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pressenza IPA\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/\"},\"author\":{\"name\":\"Pressenza IPA\",\"@id\":\"https:\/\/www.pressenza.com\/fr\/#\/schema\/person\/d6788fd25f9359ae060725fb1b8ca78c\"},\"headline\":\"La sage d\u00e9cision de l\u2019Inde\",\"datePublished\":\"2013-06-11T22:52:16+00:00\",\"dateModified\":\"2013-06-11T22:54:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/\"},\"wordCount\":285,\"publisher\":{\"@id\":\"https:\/\/www.pressenza.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.pressenza.com\/wp-content\/uploads\/2013\/06\/Medicament.jpg\",\"keywords\":[\"brevet\",\"cancer\",\"Glivec\",\"Inde\",\"m\u00e9dicament\",\"Novartis\"],\"articleSection\":[\"Asie\",\"Droits humains\",\"Economie\",\"International\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/\",\"url\":\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/\",\"name\":\"La sage d\u00e9cision de l\u2019Inde\",\"isPartOf\":{\"@id\":\"https:\/\/www.pressenza.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.pressenza.com\/wp-content\/uploads\/2013\/06\/Medicament.jpg\",\"datePublished\":\"2013-06-11T22:52:16+00:00\",\"dateModified\":\"2013-06-11T22:54:07+00:00\",\"description\":\"Par\u00a0Joseph E. Stiglitz\u00a0et\u00a0Arjun Jayadev Le rejet par la Cour Supr\u00eame de New Delhi de la demande de brevet d\u00e9pos\u00e9e par le g\u00e9ant pharmaceutique suisse\",\"breadcrumb\":{\"@id\":\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#primaryimage\",\"url\":\"https:\/\/www.pressenza.com\/wp-content\/uploads\/2013\/06\/Medicament.jpg\",\"contentUrl\":\"https:\/\/www.pressenza.com\/wp-content\/uploads\/2013\/06\/Medicament.jpg\",\"width\":800,\"height\":532},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.pressenza.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La sage d\u00e9cision de l\u2019Inde\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.pressenza.com\/fr\/#website\",\"url\":\"https:\/\/www.pressenza.com\/fr\/\",\"name\":\"Pressenza\",\"description\":\"International Press Agency\",\"publisher\":{\"@id\":\"https:\/\/www.pressenza.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.pressenza.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.pressenza.com\/fr\/#organization\",\"name\":\"Pressenza\",\"url\":\"https:\/\/www.pressenza.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.pressenza.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.pressenza.com\/wp-content\/uploads\/2022\/10\/pressenza_logo_200x200.jpg\",\"contentUrl\":\"https:\/\/www.pressenza.com\/wp-content\/uploads\/2022\/10\/pressenza_logo_200x200.jpg\",\"width\":200,\"height\":200,\"caption\":\"Pressenza\"},\"image\":{\"@id\":\"https:\/\/www.pressenza.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/PressenzaItalia\",\"https:\/\/x.com\/PressenzaIPA\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.pressenza.com\/fr\/#\/schema\/person\/d6788fd25f9359ae060725fb1b8ca78c\",\"name\":\"Pressenza IPA\",\"description\":\"News from Pressenza IPA correspondents\",\"sameAs\":[\"https:\/\/www.facebook.com\/pressenza\",\"https:\/\/x.com\/PressenzaIPA\"],\"url\":\"https:\/\/www.pressenza.com\/fr\/author\/pressenza-ipa\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La sage d\u00e9cision de l\u2019Inde","description":"Par\u00a0Joseph E. Stiglitz\u00a0et\u00a0Arjun Jayadev Le rejet par la Cour Supr\u00eame de New Delhi de la demande de brevet d\u00e9pos\u00e9e par le g\u00e9ant pharmaceutique suisse","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/","og_locale":"fr_FR","og_type":"article","og_title":"La sage d\u00e9cision de l\u2019Inde","og_description":"Par\u00a0Joseph E. Stiglitz\u00a0et\u00a0Arjun Jayadev Le rejet par la Cour Supr\u00eame de New Delhi de la demande de brevet d\u00e9pos\u00e9e par le g\u00e9ant pharmaceutique suisse","og_url":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/","og_site_name":"Pressenza","article_publisher":"https:\/\/www.facebook.com\/PressenzaItalia","article_author":"https:\/\/www.facebook.com\/pressenza","article_published_time":"2013-06-11T22:52:16+00:00","article_modified_time":"2013-06-11T22:54:07+00:00","og_image":[{"width":800,"height":532,"url":"https:\/\/www.pressenza.com\/wp-content\/uploads\/2013\/06\/Medicament.jpg","type":"image\/jpeg"}],"author":"Pressenza IPA","twitter_card":"summary_large_image","twitter_creator":"@PressenzaIPA","twitter_site":"@PressenzaIPA","twitter_misc":{"\u00c9crit par":"Pressenza IPA","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#article","isPartOf":{"@id":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/"},"author":{"name":"Pressenza IPA","@id":"https:\/\/www.pressenza.com\/fr\/#\/schema\/person\/d6788fd25f9359ae060725fb1b8ca78c"},"headline":"La sage d\u00e9cision de l\u2019Inde","datePublished":"2013-06-11T22:52:16+00:00","dateModified":"2013-06-11T22:54:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/"},"wordCount":285,"publisher":{"@id":"https:\/\/www.pressenza.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pressenza.com\/wp-content\/uploads\/2013\/06\/Medicament.jpg","keywords":["brevet","cancer","Glivec","Inde","m\u00e9dicament","Novartis"],"articleSection":["Asie","Droits humains","Economie","International"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/","url":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/","name":"La sage d\u00e9cision de l\u2019Inde","isPartOf":{"@id":"https:\/\/www.pressenza.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#primaryimage"},"image":{"@id":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pressenza.com\/wp-content\/uploads\/2013\/06\/Medicament.jpg","datePublished":"2013-06-11T22:52:16+00:00","dateModified":"2013-06-11T22:54:07+00:00","description":"Par\u00a0Joseph E. Stiglitz\u00a0et\u00a0Arjun Jayadev Le rejet par la Cour Supr\u00eame de New Delhi de la demande de brevet d\u00e9pos\u00e9e par le g\u00e9ant pharmaceutique suisse","breadcrumb":{"@id":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#primaryimage","url":"https:\/\/www.pressenza.com\/wp-content\/uploads\/2013\/06\/Medicament.jpg","contentUrl":"https:\/\/www.pressenza.com\/wp-content\/uploads\/2013\/06\/Medicament.jpg","width":800,"height":532},{"@type":"BreadcrumbList","@id":"https:\/\/www.pressenza.com\/fr\/2013\/06\/la-sage-decision-de-linde-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.pressenza.com\/fr\/"},{"@type":"ListItem","position":2,"name":"La sage d\u00e9cision de l\u2019Inde"}]},{"@type":"WebSite","@id":"https:\/\/www.pressenza.com\/fr\/#website","url":"https:\/\/www.pressenza.com\/fr\/","name":"Pressenza","description":"International Press Agency","publisher":{"@id":"https:\/\/www.pressenza.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pressenza.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.pressenza.com\/fr\/#organization","name":"Pressenza","url":"https:\/\/www.pressenza.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.pressenza.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.pressenza.com\/wp-content\/uploads\/2022\/10\/pressenza_logo_200x200.jpg","contentUrl":"https:\/\/www.pressenza.com\/wp-content\/uploads\/2022\/10\/pressenza_logo_200x200.jpg","width":200,"height":200,"caption":"Pressenza"},"image":{"@id":"https:\/\/www.pressenza.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/PressenzaItalia","https:\/\/x.com\/PressenzaIPA"]},{"@type":"Person","@id":"https:\/\/www.pressenza.com\/fr\/#\/schema\/person\/d6788fd25f9359ae060725fb1b8ca78c","name":"Pressenza IPA","description":"News from Pressenza IPA correspondents","sameAs":["https:\/\/www.facebook.com\/pressenza","https:\/\/x.com\/PressenzaIPA"],"url":"https:\/\/www.pressenza.com\/fr\/author\/pressenza-ipa\/"}]}},"place":"New York","original_article_url":"","_links":{"self":[{"href":"https:\/\/www.pressenza.com\/fr\/wp-json\/wp\/v2\/posts\/56201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pressenza.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pressenza.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pressenza.com\/fr\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pressenza.com\/fr\/wp-json\/wp\/v2\/comments?post=56201"}],"version-history":[{"count":0,"href":"https:\/\/www.pressenza.com\/fr\/wp-json\/wp\/v2\/posts\/56201\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pressenza.com\/fr\/wp-json\/wp\/v2\/media\/56205"}],"wp:attachment":[{"href":"https:\/\/www.pressenza.com\/fr\/wp-json\/wp\/v2\/media?parent=56201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pressenza.com\/fr\/wp-json\/wp\/v2\/categories?post=56201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pressenza.com\/fr\/wp-json\/wp\/v2\/tags?post=56201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}